Intelligent Bio Solutions partners with Cliantha Research to conduct study

Intelligent Bio Solutions announced its partnership with Cliantha Research, a full-service Clinical Research Organization, to perform a pharmacokinetic study forming part of the Company’s FDA 510(k) clinical study plan. The Company’s PK study will recruit 40 healthy adult subjects under an IRB/EC and regulatory approved protocol and compare the amounts of opiates in fingerprint sweat versus blood, oral fluid and urine specimens following the medically supervised administration of drugs. Harry Simeonidis, President and CEO at Intelligent Bio Solutions, commented, “We are pleased to share news of our partnership with Cliantha and progress on our 510(k) journey. Initiating our clinical studies plan represents a critical milestone for our organization. We have developed a detailed plan that we are committed to executing, and while there is considerable work ahead, we have taken the crucial first step in this process. Our focus is on ensuring we remain on track for our planned entry into the US market and expand access to our innovative screening solution.”